Drugmaker Eli Lilly starts clinical testing of therapies for COVID-19 [Yahoo! Finance News]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance News
April 10 ) - U.S. Drugmaker Eli Lilly & Co said on Friday it began clinical testing of therapies for the COVID-19 illness caused by the coronavirus.The company said it had entered into an agreement with the National Institute of Allergy and Infectious Diseases to study the baricitinib drug to examine its efficacy and safety as a potential treatment for hospitalized patients diagnosed with COVID-19.Lilly had previously been testing the Olumiant or baricitinib drug as a treatment for atopic dermatitis.The study will start this month in the United States and will then expand to other sites in Europe and Asia, the company said in a statement, adding results from the study are expected within two months.Lilly said it currently does not anticipate shortages for any of its medicines, including baricitinib.U.S. deaths due to the coronavirus topped 18,100 on Friday, according to a tally.Earlier this week, the drugmaker lowered insulin costs, saying it has capped the out-of-pocket cost for it
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (NYSE:LLY) had its price target lowered by analysts at Guggenheim from $1,163.00 to $1,161.00. They now have a "buy" rating on the stock.MarketBeat
- Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancerPR Newswire
- Smaller portions, more protein: How GLP-1s are quietly changing chain restaurant menus [MSNBC.com]MSNBC.com
- Prediction: 2026 Will Be the Year of Eli Lilly [Yahoo! Finance]Yahoo! Finance
- What Eli Lilly (LLY)'s NVIDIA AI Lab And Obesity Data Reveal About Its Obesity Leadership Narrative [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 1/8/26 - Form 4
- 1/6/26 - Form 3
- 1/6/26 - Form 4
- LLY's page on the SEC website